C
Christopher Stroh
Researcher at Merck KGaA
Publications - 23
Citations - 3848
Christopher Stroh is an academic researcher from Merck KGaA. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 6, co-authored 11 publications receiving 3527 citations.
Papers
More filters
Journal ArticleDOI
The Preclinical Pharmacology of Tepotinib—A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations
Joachim Albers,Manja Friese-Hamim,Anderson Clark,Oliver Schadt,Gina Walter-Bausch,Christopher Stroh,Andreas Johne,Niki Karachaliou,Andree Blaukat +8 more
TL;DR: In this article , the mesenchymal-epithelial transition factor (MET) proto-oncogene encodes the MET receptor tyrosine kinase, which is a therapeutic target and the selective type Ib MET inhibitor, tepotinib, was designed to potently inhibit MET kinase activity.
Journal ArticleDOI
Treatment outcomes in patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC) harboring MET amplification as a secondary oncogenic driver.
TL;DR: In this paper , a non-interventional, descriptive cohort study design was applied using ConcertAI electronic medical record data derived from US community oncology centers and linked with ASCO/CancerLinQ data.
Journal ArticleDOI
Biomarker testing and treatment patterns in US patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC) harboring MET amplification.
Alex B. Ryder,D. Oksen,Emmanuelle Boutmy,Yuexi Wang,Alnecia R Nisbett,Christopher Stroh,Andreas Johne +6 more
TL;DR: In this article , a non-interventional, descriptive cohort study using ConcertAI electronic medical record data derived from US community oncology centers and linked with ASCO/CancerLinQ data was conducted.